NFKB1 and HIV-associated neurocognitive disorder: We found that JWH-133 agonist treatment downregulated several proteins associated with NF-κB signaling, the Nrf2-mediated oxidative stress response, and lysosomal exocytosis in HIV-MDM, warranting in vivo studies to test its potential against HAND [15].